PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN- production

Science Translational Medicine

Volumn 10, Issue 440, 2018, Pages

  Werder, Rhiannon B ^a   Lynch, Jason P ^a   Simpson, Jennifer C ^a,b   Zhang, Vivian ^b   Hodge, Nick H ^a   Poh, Matthew ^c   Forbes Blom, Elizabeth ^d   Kulis, Christina ^a   Smythe, Mark L ^a   Upham, John W ^a   Spann, Kirsten ^a,e   Everard, Mark L ^c   Phipps, Simon ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

15 METHYLPROSTAGLANDIN D2; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; AM 156; GAMMA INTERFERON; INTERLEUKIN 28A; INTERLEUKIN 28B; LAROPIPRANT; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN D2 DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; [2' [(CYCLOPROPANECARBONYLETHYLAMINO)METHYL] 6 METHOXY 4' TRIFLUOROMETHYLBIPHENYL 3 YL]ACETIC ACID; ALLERGEN; ANTIVIRUS AGENT; HPGDS PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; ISOMERASE; PROSTANOID D RECEPTOR 1, MOUSE;

AIRWAY EPITHELIUM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFECT; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFANT; MORBIDITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; UPREGULATION; VIRAL BRONCHIOLITIS; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; EPITHELIUM CELL; IMMUNITY; INFLAMMATION; LUNG; METABOLISM; MURINE PNEUMONIA VIRUS; PATHOLOGY; PHYSIOLOGY; PNEUMOVIRUS; VIROLOGY;

ALLERGENS; ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; BRONCHIOLITIS, VIRAL; EPITHELIAL CELLS; HUMANS; IMMUNITY; INFANT; INFLAMMATION; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; LUNG; MICE, INBRED BALB C; MURINE PNEUMONIA VIRUS; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; UP-REGULATION;

EID: 85047061274     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aao0052     Document Type: Article

References (65)

1. B. N. Lambrecht, H. Hammad, The immunology of asthma. Nat. Immunol. 16, 45–56 (2015).
2. G. F. Sonnenberg, D. Artis, Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat. Med. 21, 698–708 (2015).
3. J. J. Murray, A. B. Tonnel, A. R. Brash, L. J. Roberts II, P. Gosset, R. Workman, A. Capron, J. A. Oates, Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med. 315, 800–804 (1986).
4. R. W. Fuller, C. M. S. Dixon, C. T. Dollery, P. J. Barnes, Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am. Rev. Respir. Dis. 133, 252–254 (1986).
5. L. Xue, M. Salimi, I. Panse, J. M. Mjösberg, A. N. J. McKenzie, H. Spits, P. Klenerman, G. Ogg, Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J. Allergy Clin. Immunol. 133, 1184–1194.e7 (2014).
6. H. Hirai, K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S. Takano, K. Nagata, Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193, 255–261 (2001).
7. P. J. Barnes, New therapies for asthma: Is there any progress? Trends Pharmacol. Sci. 31, 335–343 (2010).
8. P. Gosset, F. Bureau, V. Angeli, M. Pichavant, C. Faveeuw, A.-B. Tonnel, F. Trottein, Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: Consequence on the polarization of naive Th cells. J. Immunol. 170, 4943–4952 (2003).
9. H. Hammad, M. Kool, T. Soullié, S. Narumiya, F. Trottein, H. C. Hoogsteden, B. N. Lambrecht, Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J. Exp. Med. 204, 357–367 (2007).
10. G. Bain, D. S. Lorrain, K. J. Stebbins, A. R. Broadhead, A. M. Santini, P. Prodanovich, J. Darlington, C. D. King, C. Lee, C. Baccei, B. Stearns, Y. Troung, J. H. Hutchinson, P. Prasit, J. F. Evans, Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J. Pharmacol. Exp. Ther. 338, 290–301 (2011).
11. K. J. Stebbins, A. R. Broadhead, L. D. Correa, J. M. Scott, Y. P. Truong, B. A. Stearns, J. H. Hutchinson, P. Prasit, J. F. Evans, D. S. Lorrain, Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur. J. Pharmacol. 638, 142–149 (2010).
12. Z. Diamant, P. N. Sidharta, D. Singh, B. J. O’Connor, R. Zuiker, B. R. Leaker, M. Silkey, J. Dingemanse, Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin. Exp. Allergy 44, 1044–1052 (2014).
13. S. Gonem, R. Berair, A. Singapuri, R. Hartley, M. F. M. Laurencin, G. Bacher, B. Holzhauer, M. Bourne, V. Mistry, I. D. Pavord, A. H. Mansur, A. J. Wardlaw, S. H. Siddiqui, R. A. Kay, C. E. Brightling, Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: A single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir. Med. 4, 699–707 (2016).
14. W. W. Busse, S. E. Wenzel, E. O. Meltzer, E. M. Kerwin, M. C. Liu, N. Zhang, Y. Chon, A. L. Budelsky, J. Lin, S. L. Lin, Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J. Allergy Clin. Immunol. 131, 339–345 (2013).
15. K. M. James, T. Gebretsadik, G. J. Escobar, P. Wu, K. N. Carroll, S. X. Li, E. M. Walsh, E. F. Mitchel, C. D. Sloan, T. V. Hartert, Risk of childhood asthma following infant bronchiolitis during the respiratory syncytial virus season. J. Allergy Clin. Immunol. 132, 227–229 (2013).
16. D. J. Jackson, R. E. Gangnon, M. D. Evans, K. A. Roberg, E. L. Anderson, T. E. Pappas, M. C. Printz, W.-M. Lee, P. A. Shult, E. Reisdorf, K. T. Carlson-Dakes, L. P. Salazar, D. F. DaSilva, C. J. Tisler, J. E. Gern, R. F. Lemanske Jr., Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med. 178, 667–672 (2008).
17. P. G. Holt, J. Rowe, M. Kusel, F. Parsons, E. M. Hollams, A. Bosco, K. McKenna, L. Subrata, N. de Klerk, M. Serralha, B. J. Holt, G. Zhang, R. Loh, S. Ahlstedt, P. D. Sly, Toward improved prediction of risk for atopy and asthma among preschoolers: A prospective cohort study. J. Allergy Clin. Immunol. 125, 653–659.e7 (2010).
18. D. J. Jackson, M. D. Evans, R. E. Gangnon, C. J. Tisler, T. E. Pappas, W.-M. Lee, J. E. Gern, R. F. Lemanske Jr., Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am. J. Respir. Crit. Care Med. 185, 281–285 (2012).
19. J. P. Lynch, R. B. Werder, J. Simpson, Z. Loh, V. Zhang, A. Haque, K. Spann, P. D. Sly, S. B. Mazzone, J. W. Upham, S. Phipps, Aeroallergen-induced IL-33 predisposes to respiratory virus–induced asthma by dampening antiviral immunity. J. Allergy Clin. Immunol. 138, 1326–1337 (2016).
20. M. Contoli, K. Ito, A. Padovani, D. Poletti, B. Marku, M. R. Edwards, L. A. Stanciu, G. Gnesini, A. Pastore, A. Spanevello, P. Morelli, S. L. Johnston, G. Caramori, A. Papi, TH2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy 70, 910–920 (2015).
21. R. B. Werder, V. Z. Zhang, J. P. Lynch, N. Snape, J. W. Upham, K. Spann, S. Phipps, Chronic IL-33 expression predisposes to virus-induced asthma exacerbations by increasing type 2 inflammation and dampening antiviral immunity. J. Allergy Clin. Immunol. 10.1016/j.jaci.2017.07.051(2017).
22. A. S. Feldman, Y. He, M. L. Moore, M. B. Hershenson, T. V. Hartert, Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am. J. Respir. Crit. Care Med. 191, 34–44 (2015).
23. Y. Kanaoka, Y. Urade, Hematopoietic prostaglandin D synthase. Prostaglandins Leukot. Essent. Fatty Acids 69, 163–167 (2003).
24. Y. Urade, O. Hayaishi, Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim. Biophys. Acta 1482, 259–271 (2000).
25. G. M. Levasseur-Acker, M. Molimard, J. Regnard, E. Naline, C. Freche, A. Lockhart, Effect of furosemide on prostaglandin synthesis by human nasal and bronchial epithelial cells in culture. Am. J. Respir. Cell Mol. Biol. 10, 378–383 (1994).
26. A. Roulston, R. C. Marcellus, P. E. Branton, Viruses and apoptosis. Annu. Rev. Microbiol. 53, 577–628 (1999).
27. J. P. Legg, I. R. Hussain, J. A. Warner, S. L. Johnston, J. O. Warner, Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 168, 633–639 (2003).
28. C. A. Lindemans, J. L. L. Kimpen, B. Luijk, J. Heidema, D. Kanters, C. K. van der Ent, L. Koenderman, Systemic eosinophil response induced by respiratory syncytial virus. Clin. Exp. Immunol. 144, 409–417 (2006).
29. S. Baraldo, M. Contoli, E. Bazzan, G. Turato, A. Padovani, B. Marku, F. Calabrese, G. Caramori, A. Ballarin, D. Snijders, A. Barbato, M. Saetta, A. Papi, Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma. J. Allergy Clin. Immunol. 130, 1307–1314 (2012).
30. R. O’Reilly, N. Ullmann, S. Irving, C. J. Bossley, S. Sonnappa, J. Zhu, T. Oates, W. Banya, P. K. Jeffery, A. Bush, S. Saglani, Increased airway smooth muscle in preschool wheezers who have asthma at school age. J. Allergy Clin. Immunol. 131, 1024–1032 (2013).
31. I. Ioannidis, F. Ye, B. McNally, M. Willette, E. Flaño, Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J. Virol. 87, 3261–3270 (2013).
32. S. C. Buckingham, A. J. Bush, J. P. Devincenzo, Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr. Infect. Dis. J. 19, 113–117 (2000).
33. R. Nenna, M. Ferrara, A. Nicolai, A. Pierangeli, C. Scagnolari, P. Papoff, G. Antonelli, C. Moretti, F. Midulla, Viral load in infants hospitalized for respiratory syncytial virus bronchiolitis correlates with recurrent wheezing at thirty-six-month follow-up. Pediatr. Infect. Dis. J. 34, 1131–1132 (2015).
34. K. M. Spann, K.-C. Tran, B. Chi, R. L. Rabin, P. L. Collins, Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J. Virol. 78, 4363–4369 (2004).
35. A. A. Bakre, J. L. Harcourt, L. M. Haynes, L. J. Anderson, R. A. Tripp, The central conserved region (CCR) of respiratory syncytial virus (RSV) G protein modulates host miRNA expression and alters the cellular response to infection. Vaccines 5, E16 (2017).
36. R. Janssen, L. Bont, C. L. E. Siezen, H. M. Hodemaekers, M. J. Ermers, G. Doornbos, R. van’t Slot, C. Wijmenga, J. J. Goeman, J. L. L. Kimpen, H. C. van Houwelingen, T. G. Kimman, B. Hoebee, Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J. Infect. Dis. 196, 826–834 (2007).
37. A. Pasanen, M. K. Karjalainen, L. Bont, E. Piippo-Savolainen, M. Ruotsalainen, E. Goksör, K. Kumawat, H. Hodemaekers, K. Nuolivirta, T. Jartti, G. Wennergren, M. Hallman, M. Rämet, M. Korppi, Genome-wide association study of polymorphisms predisposing to bronchiolitis. Sci. Rep. 7, 41653 (2017).
38. R. C. Benyon, C. Robinson, M. K. Church, Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br. J. Pharmacol. 97, 898–904 (1989).
39. I. E. Galani, V. Triantafyllia, E.-E. Eleminiadou, O. Koltsida, A. Stavropoulos, M. Manioudaki, D. Thanos, S. E. Doyle, S. V. Kotenko, K. Thanopoulou, E. Andreakos, Interferon- mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46, 875–890.e6 (2017).
40. R. Pettipher, T. T. Hansel, R. Armer, Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6, 313–325 (2007).
41. K. J. Stebbins, A. R. Broadhead, A. Musiyenko, S. Barik, J. M. Scott, Y. P. Truong, B. A. Stearns, J. H. Hutchinson, P. Prasit, J. F. Evans, D. S. Lorrain, DP2 (CRTH2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus. Int. Arch. Allergy Immunol. 157, 259–268 (2012).
42. M. Contoli, S. D. Message, V. Laza-Stanca, M. R. Edwards, P. A. B. Wark, N. W. Bartlett, T. Kebadze, P. Mallia, L. A. Stanciu, H. L. Parker, L. Slater, A. Lewis-Antes, O. M. Kon, S. T. Holgate, D. E. Davies, S. V. Kotenko, A. Papi, S. L. Johnston, Role of deficient type III interferon- production in asthma exacerbations. Nat. Med. 12, 1023–1026 (2006).
43. P. A. B. Wark, S. L. Johnston, F. Bucchieri, R. Powell, S. Puddicombe, V. Laza-Stanca, S. T. Holgate, D. E. Davies, Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 201, 937–947 (2005).
44. K. M. Spann, E. Baturcam, J. Schagen, C. Jones, C. P. Straub, F. M. Preston, L. Chen, S. Phipps, P. D. Sly, E. Fantino, Viral and host factors determine innate immune responses in airway epithelial cells from children with wheeze and atopy. Thorax 69, 918–925 (2014).
45. Y. A. Bochkov, K. M. Hanson, S. Keles, R. A. Brockman-Schneider, N. N. Jarjour, J. E. Gern, Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 3, 69–80 (2010).
46. N. Lopez-Souza, S. Favoreto, H. Wong, T. Ward, S. Yagi, D. Schnurr, W. E. Finkbeiner, G. M. Dolganov, J. H. Widdicombe, H. A. Boushey, P. C. Avila, In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J. Allergy Clin. Immunol. 123, 1384–1390.e2 (2009).
47. D. Van Ly, A. Faiz, C. Jenkins, B. Crossett, J. L. Black, B. McParland, J. K. Burgess, B. G. G. Oliver, Characterising the mechanism of airway smooth muscle 2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLOS ONE 8, e56058 (2013).
48. S. Wenzel, L. Ford, D. Pearlman, S. Spector, L. Sher, F. Skobieranda, L. Wang, S. Kirkesseli, R. Rocklin, B. Bock, J. Hamilton, J. E. Ming, A. Radin, N. Stahl, G. D. Yancopoulos, N. Graham, G. Pirozzi Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455–2466 (2013).
49. I. D. Pavord, S. Korn, P. Howarth, E. R. Bleecker, R. Buhl, O. N. Keene, H. Ortega, P. Chanez, Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 380, 651–659 (2012).
50. E. Ricciotti, G. A. FitzGerald, Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986–1000 (2011).
51. M. L. Fajt, S. L. Gelhaus, B. Freeman, C. E. Uvalle, J. B. Trudeau, F. Holguin, S. E. Wenzel, Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammation. J. Allergy Clin. Immunol. 131, 1504–1512 (2013).
52. L. Gazi, S. Gyles, J. Rose, S. Lees, C. Allan, L. Xue, R. Jassal, G. Speight, V. Gamble, R. Pettipher, 12-Prostaglandin D2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and TH2 lymphocytes. Prostaglandins Other Lipid Mediat. 75, 153–167 (2005).
53. 12-Prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J. Immunol. 170, 4752–4758 (2003).
54. R. Schuligoi, R. Schmidt, G. Geisslinger, M. Kollroser, B. A. Peskar, A. Heinemann, PGD2 metabolism in plasma: Kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem. Pharmacol. 74, 107–117 (2007).
55. R. Arnold, W. König, Peroxisome proliferator-activated receptor- agonists inhibit the replication of syncytial virus (RSV) in human lung epithelial cells. Virology 350, 335–346 (2006).
56. S. Davidson, G. Kaiko, Z. Loh, A. Lalwani, V. Zhang, K. Spann, S. Y. Foo, N. Hansbro, S. Uematsu, S. Akira, K. I. Matthaei, H. F. Rosenberg, P. S. Foster, S. Phipps, Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway. J. Immunol. 186, 5938–5948 (2011).
57. K. J. Stebbins, A. R. Broadhead, C. S. Baccei, J. M. Scott, Y. P. Truong, H. Coate, N. S. Stock, A. M. Santini, P. Fagan, P. Prodanovich, G. Bain, B. A. Stearns, C. D. King, J. H. Hutchinson, P. Prasit, J. F. Evans, D. S. Lorrain, Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung. J. Pharmacol. Exp. Ther. 332, 764–775 (2010).
58. K. Cheng, T.-J. Wu, K. K. Wu, C. Sturino, K. Metters, K. Gottesdiener, S. D. Wright, Z. Wang, G. O’Neill, E. Lai, M. G. Waters, Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 103, 6682–6687 (2006).
59. K. Kobayashi, Y. Tsubosaka, M. Hori, S. Narumiya, H. Ozaki, T. Murata, Prostaglandin D2-DP signaling promotes endothelial barrier function via the cAMP/PKA/Tiam1/Rac1 pathway. Arterioscler. Thromb. Vasc. Biol. 33, 565–571 (2013).
60. G. Monneret, C. Cossette, S. Gravel, J. Rokach, W. S. Powell, 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. J. Pharmacol. Exp. Ther. 304, 349–355 (2003).
61. J. R. Rock, M. W. Onaitis, E. L. Rawlins, Y. Lu, C. P. Clark, Y. Xue, S. H. Randell, B. L. M. Hogan, Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. 106, 12771–12775 (2009).
62. M. E. Lauer, D. Mukhopadhyay, C. Fulop, C. A. de la Motte, A. K. Majors, V. C. Hascall, Primary murine airway smooth muscle cells exposed to poly(I,C) or tunicamycin synthesize a leukocyte-adhesive hyaluronan matrix. J. Biol. Chem. 284, 5299–5312 (2009).
63. G. E. Kaiko, Z. Loh, K. Spann, J. P. Lynch, A. Lalwani, Z. Zheng, S. Davidson, S. Uematsu, S. Akira, J. Hayball, K. R. Diener, K. J. Baines, J. L. Simpson, P. G. Gibson, P. S. Foster, S. Phipps, Toll-like receptor 7 gene deficiency and early-life Pneumovirus infection interact to predispose toward the development of asthma-like pathology in mice. J. Allergy Clin. Immunol. 131, 1331–1339.e10 (2013).
64. J. Arikkatt, M. A. Ullah, K. R. Short, V. Zhang, W. J. Gan, Z. Loh, R. B. Werder, J. Simpson, P. D. Sly, S. B. Mazzone, K. M. Spann, M. A. R. Ferreira, J. W. Upham, M. B. Sukkar, S. Phipps, RAGE deficiency predisposes mice to virus-induced paucigranulocytic asthma. eLife 6, e21199 (2017).
65. E. Baturcam, N. Snape, T. H. Yeo, J. Schagen, E. Thomas, J. Logan, S. Galbraith, N. Collinson, S. Phipps, E. Fantino, P. D. Sly, K. M. Spann, Human metapneumovirus impairs apoptosis of nasal epithelial cells in asthma via HSP70. J. Innate Immun. 9, 52–64 (2017).